Iud Or Ring Patents (Class 424/432)
-
Patent number: 7883718Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: GrantFiled: May 22, 2008Date of Patent: February 8, 2011Assignee: The General Hospital CorporationInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, Jr.
-
Publication number: 20110020423Abstract: Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.Type: ApplicationFiled: July 21, 2010Publication date: January 27, 2011Applicant: PureTech VenturesInventors: Eric Elenko, Andrew C. Miller, Philip E. Murray, III
-
Publication number: 20100330138Abstract: Biostable, multipurpose, microbicidal intravaginal devices in the form of rings, ringed-meshes, sponges, or diaphragms for use by women and condoms for use by male partners are provided, wherein each of the devices contains a drug effective in treating a particular vaginal infection, while further exhibiting at least one additional function selected from the group dealing with non-hormonal contraception, management of sexually transmitted diseases, viral infections, and retroviral infections as well as the treatment of cervical cancer.Type: ApplicationFiled: May 11, 2009Publication date: December 30, 2010Inventors: Shalaby W. Shalaby, Georgios T. Hilas
-
Patent number: 7850986Abstract: The present invention relates to a delivery system comprising a core and a membrane encasing said core, wherein said core and membrane consist essentially of an elastomer composition and said core comprises at least one therapeutically active agent. The delivery system is characterized in that the membrane comprises at least one regulating agent. The invention also relates to a method for controlling the release of at least one therapeutically active agent from a delivery system.Type: GrantFiled: July 5, 2005Date of Patent: December 14, 2010Assignee: Schering OyInventor: Teppo Riihimäki
-
Patent number: 7838024Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: GrantFiled: May 22, 2008Date of Patent: November 23, 2010Assignees: The General Hospital Corporation, Massachusetts Institute of TechnologyInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, Jr.
-
Patent number: 7833545Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: GrantFiled: April 29, 2004Date of Patent: November 16, 2010Assignee: The General Hospital CorporationInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, Jr.
-
Publication number: 20100285097Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.Type: ApplicationFiled: November 19, 2008Publication date: November 11, 2010Inventors: Christine Talling, Vladimir Hanes, Antti Keinänen, Svante Holmberg, Hannu Nikander
-
Patent number: 7829112Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: GrantFiled: May 22, 2008Date of Patent: November 9, 2010Assignee: The General Hospital CorporationInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, Jr.
-
Patent number: 7824383Abstract: A vaginal drug delivery system includes a device formed of porous material that holds a flowable therapeutic formulation. The device, preferably in a soft, prewetted state, is inserted into the vagina to reside typically at or near the cervix where it continuously releases the flowable therapeutic formulation through its outer surface which is in contact with the vaginal surfaces. In operation, the flowable therapeutic formulation migrates via capillary forces from a reservoir that is centrally located in the device and through a covering that envelopes the reservoir.Type: GrantFiled: June 14, 2007Date of Patent: November 2, 2010Assignee: Family Health InternationalInventors: David C. Sokal, Carol L. Joanis, George A. M. Butterworth, James D. Reed, Robert A. Johnson
-
Patent number: 7803574Abstract: This invention provides novel nanofiber enhanced surface area substrates and structures comprising such substrates for use in various medical devices, as well as methods and uses for such substrates and medical devices. In one particular embodiment, a method of administering a composition to a patient is disclosed which comprises providing a composition-eluting device, said composition-eluting device comprising at least a first surface and a plurality of nanostructures attached to the first surface, and introducing the composition-eluting device into the body of the patient.Type: GrantFiled: February 22, 2007Date of Patent: September 28, 2010Assignee: Nanosys, Inc.Inventors: Tejal Desai, R. Hugh Daniels, Vijendra Sahi
-
Publication number: 20100203104Abstract: This invention relates to an extended release formulation comprising solid risperidone, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing risperidone. The polymer is preferably made of ethylene-vinyl acetate copolymer.Type: ApplicationFiled: November 21, 2007Publication date: August 12, 2010Inventors: Wouter De Graaff, Armin Szegedi
-
Patent number: 7744916Abstract: A vaginal device for delivery of an anti-migraine or anti-nausea drug to the uterus and/or to the general circulation through vaginal mucosa. The device is at least partially coated with one or several layers of fluid impermeable material forming a cap, film, foam, foil or strip incorporated with mucoadhesive composition comprising the anti-migraine or anti-nausea drug.Type: GrantFiled: May 10, 2005Date of Patent: June 29, 2010Assignee: UMD, Inc.Inventors: Giovanni M. Pauletti, Michelle Wilson, Richard Soderstrom, Desai J. Kishorkumar, Wolfgang A. Ritschel
-
Publication number: 20100136090Abstract: The present invention relates to a helically-shaped medicated veterinary system suitable for delivery of a drug to the vaginal cavity of a female non-human mammal and to a method of manufacture. The drug delivery system is helically-shaped and comprises a three layered polymer fibre. The polymer fibre comprises a polymer core, a polymer intermediate layer comprising a drug, and a polymer skin. The medicated system provides a controlled delivery of drug to the vaginal cavity of the mammal. The present invention also relates to a process of making the springs.Type: ApplicationFiled: November 19, 2007Publication date: June 3, 2010Inventors: Marc-Antoine Driancourt, Wouter De Graff, Laura Buttafoco, Fabrice Payot, Harm Veenstra, René Willem Joris Voss
-
Publication number: 20100129425Abstract: This invention relates to an extended release formulation comprising solid mirtazapine, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing mirtazapine. The polymer is preferably made of ethylene-vinyl acetate copolymer.Type: ApplicationFiled: November 21, 2007Publication date: May 27, 2010Inventors: Wouter De Graaff, Armin Szegedi
-
Patent number: 7691403Abstract: Non-absorbent articles containing an additive are disclosed. The non-absorbent articles include an effective amount of an inhibitory compound such as cerulenin, triclosan, or hexachloroprene, for example, to substantially inhibit the production of TSST-1 by Gram positive bacteria.Type: GrantFiled: October 16, 2002Date of Patent: April 6, 2010Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Rae Ellen Syverson, Richard A. Proctor
-
Publication number: 20100062039Abstract: This invention generally covers a ringed-mesh intravaginal device and applicator therefore wherein the ringed-mesh comprises a composite ring comprising a flexible matrix containing one or more bioactive agent or agents and needed excipients or modulators, and the said matrix is reinforced with a fibrous construct to provided needed initial and in-use biomechanical stability. Of special application of the medicated, ringed-mesh is its use for securing contraception relying on biomechanical, pharmacological, and biochemical means.Type: ApplicationFiled: December 14, 2005Publication date: March 11, 2010Inventor: Shalaby W. Shalaby
-
Publication number: 20100040671Abstract: The present invention relates to intravaginal devices having a rigid support, methods of making, and uses thereof. The devices comprise (a) a rigid support having a Shore A Hardness of at least about 20 and a tensile strength of at least about 1 MPa, (b) a matrix, and (c) an active agent dispersed in the matrix, wherein the support and the matrix are adjacent and wherein the device is annular.Type: ApplicationFiled: August 11, 2009Publication date: February 18, 2010Inventors: Salah U. AHMED, Jiaxiang Tsao
-
Publication number: 20100034863Abstract: Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.Type: ApplicationFiled: February 12, 2008Publication date: February 11, 2010Inventors: David Fairhurst, Garry Thomas Gwozdz, Mark Mitchnick, Abhijit Gokhale, Andrew Loxley
-
Publication number: 20090324692Abstract: A linear polymer is obtained by reacting together a polyethylene glycol or polypropylene glycol; a PEG-PPG-PEG or PPG-PEG-PPG block copolymer; a difunctional amine or diol; and a diisocyanate. A controlled release composition comprises the polymer together with an active agent. Active agents of molecular weight 200 to 20,000 may be used.Type: ApplicationFiled: June 27, 2007Publication date: December 31, 2009Applicant: CONTROLLED THERAPEUTICS (SCOTLAND) LIMITEDInventors: Jukka Tuominen, Amaia Zurutuza, Mark Livingstone, Janet A. Halliday
-
Publication number: 20090311306Abstract: An intrauterine contraceptive device comprising a carrier body (1) and an active metallic alloy (4), characterized in that the active metallic alloy is of the formula ZnxCuyMnzAuk (I) or ZnxCuyMnzAgk (II), wherein x+y+z+k=100 weight %, x is in the range from approximately 18 to 30 weight %, z is in the range from approximately 0.5 to 3 weight %, and k is in the range from approximately 3 to 12 weight %, y being the balance.Type: ApplicationFiled: September 20, 2007Publication date: December 17, 2009Inventor: Melinda-Kinga Karpati
-
Publication number: 20090291120Abstract: A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000.Type: ApplicationFiled: June 27, 2007Publication date: November 26, 2009Inventors: Jukka Tuominen, Amaia Zurutuza, Mark Livingston, Janet A. Halliday
-
Publication number: 20090246254Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: ApplicationFiled: April 3, 2009Publication date: October 1, 2009Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Publication number: 20090208558Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.Type: ApplicationFiled: May 10, 2007Publication date: August 20, 2009Applicant: PHARMACON-FORSCHUNG UND BERATUNG GMBHInventors: Christian Noe, Marion Noe
-
Publication number: 20090202612Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.Type: ApplicationFiled: February 3, 2009Publication date: August 13, 2009Inventors: Salah U. AHMED, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
-
Publication number: 20090123522Abstract: A medicament delivery device and method of delivering a medicament is provided wherein the device is insertable into the uterine myometrium for the delivery of medicaments to the pelvic area and organs thereof, for example, the bladder, peritoneum, the vulva, vagina, fallopian tubes, ovaries, and uterus, and then to the bloodstream.Type: ApplicationFiled: October 6, 2008Publication date: May 14, 2009Inventor: James Browning
-
Patent number: 7521064Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: GrantFiled: August 24, 2001Date of Patent: April 21, 2009Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Publication number: 20090060982Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: ApplicationFiled: May 22, 2008Publication date: March 5, 2009Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, JR.
-
Publication number: 20080286339Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.Type: ApplicationFiled: May 22, 2008Publication date: November 20, 2008Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Eyal S. Ron, Robert S. Langer, William F. Crowley, JR.
-
Patent number: 7438836Abstract: The present invention provides a dispersion, which contains nano-sized zinc oxide particles, a coating preparation containing the dispersion, a process for the production of the dispersion, and a coating preparation containing the dispersion, and a use of the coating preparation.Type: GrantFiled: January 24, 2005Date of Patent: October 21, 2008Assignee: Evonik Degussa GmbHInventors: Guenther Michael, Stefan Heberer, Ruediger Mertsch, Robert Maier, Simone Jetton, Frans De Peuter
-
Publication number: 20080206309Abstract: A method of treating menorrhagia and/or dysmenorrhoea in a patient the method comprising administering to the patient an antagonist of a prostaglandin EP2 and/or EP4 receptor. Preferably the patient is a human female.Type: ApplicationFiled: April 14, 2008Publication date: August 28, 2008Applicant: MEDICAL RESEARCH COUNCILInventors: Henry Nicolas JABBOUR, Hilary Octavia Dawn CRITCHLEY
-
Publication number: 20080206310Abstract: The subject invention provides for new regimens for contraceptive dosage forms.Type: ApplicationFiled: June 16, 2006Publication date: August 28, 2008Applicant: N.V. OraganonInventor: Victoria Jane Davis
-
Publication number: 20080199511Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.Type: ApplicationFiled: July 8, 2005Publication date: August 21, 2008Applicant: Laboratoire HRA PharmaInventors: Regine Sitruk-Ware, Yun-Yen Tsong
-
Patent number: 7262164Abstract: Thiol-linked polymeric prodrugs, methods of making and using the same are disclosed. The use of a sulfhydryl bond in combination with a benzyl elimination system results in the formation of prodrugs which can take advantage of plasma enzymes in vivo for regeneration of the parent molecule. A preferred prodrug in accordance with the invention is: where S-MP is 6-mercaptopurine.Type: GrantFiled: November 8, 2002Date of Patent: August 28, 2007Assignee: Enzon, Inc.Inventors: Yun H. Choe, Richard B. Greenwald
-
Patent number: 7041310Abstract: This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.Type: GrantFiled: March 28, 2002Date of Patent: May 9, 2006Assignees: Chisso CorporationInventors: Nobuhiko Yui, Kouichi Murakami, Tooru Ooya, Ikuo Sato
-
Patent number: 7005138Abstract: Methods and compositions are disclosed for the intravaginal or rectal delivery of selected serotonin reuptake inhibitors (SSRIs) to the systemic circulation. Such methods and compositions are useful in the treatment of depression, migraine headaches, chronic pain, psychoactive substance abuse disorders, pre-menstrual dysphoric disorder (PMDD) and obsessive compulsive disorders. The compositions may be formulated for the immediate release or controlled release of SSRIs over an extended period of time. A preferred SSRI is fluoxetine.Type: GrantFiled: March 12, 2002Date of Patent: February 28, 2006Assignee: Duramed Pharmaceuticals, Inc.Inventors: Anu Mahashabde, Martha Francine Kay, Brian Glazer, Junxiong Zhang
-
Patent number: 6951654Abstract: An intravaginal antimicrobial drug delivery device is disclosed having an antimicrobial agent dispersed throughout a biocompatible elastomeric system. Also disclosed is a method of making the antimicrobial drug delivery device.Type: GrantFiled: March 27, 2002Date of Patent: October 4, 2005Assignee: Galen (Chemicals) LimitedInventors: Karl Malcolm, David Woolfson, Grant Elliott, Martin Shephard
-
Patent number: 6899890Abstract: The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.Type: GrantFiled: March 20, 2002Date of Patent: May 31, 2005Assignee: KV Pharmaceutical CompanyInventors: Mitchell I. Kirschner, R. Saul Levinson, Thomas C. Riley, Marc S. Hermelin
-
Patent number: 6646144Abstract: The present invention relates to cranberry seed oil derivatives derived by the reaction of dimethicone copolyol and cold pressed cranberry seed oil. The choice of cold pressed cranberry seed oil as a raw material in the preparation of the compounds of the present invention is critical, since it has been found that the cold pressed cranberry seed oil contains antioxidants, antimicrobial compounds and which when reacted with a water soluble or water dispersible silicone result in products that deliver said actives to the skin and hair, resulting in protection of the skin and hair from environmental factors such as acid rain, ozone attack and UV degradation.Type: GrantFiled: November 4, 2002Date of Patent: November 11, 2003Assignee: Zenitech LLCInventors: Kenneth Klein, Irwin Paleksky, Anthony J. O'Lenick, Jr.
-
Patent number: 6596297Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one pectin, such as an apple pectin, and optionally at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.Type: GrantFiled: March 5, 2002Date of Patent: July 22, 2003Assignee: New York Blood Center, Inc.Inventors: Alexander Robert Neurath, Nathan Strick
-
Patent number: 6592894Abstract: A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca2+ or Zn2+, forms a cochleate precipitate of a particle size less than one micron. The process may be used to produce cochleates containing biologically relevant molecules.Type: GrantFiled: July 11, 2000Date of Patent: July 15, 2003Assignees: BioDelivery Sciences International, Inc., University of Medicine and Dentistry of New JerseyInventors: Leila Zarif, Tuo Jin, Ignacio Segarra, Raphael J. Mannino
-
Patent number: 6572875Abstract: An intravaginal bio-erodible microbicidal barrier device. The device comprises (a) at least one micronized compound selected from the group consisting of cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, and (b) at least one water soluble or water dispersible cellulose compound selected from the group consisting of hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxyethylethylcellulose and hydroxypropylethylcellulose. The device is prepared by a combination of foaming, freezing and freeze-drying processes.Type: GrantFiled: September 28, 2001Date of Patent: June 3, 2003Assignee: New York Blood Center, Inc.Inventors: Alexander Robert Neurath, Nathan Strick
-
Patent number: 6544546Abstract: A ring-shaped device for controlled release of hormonal compounds comprising a first compartment having a non-medicated core of ethylene-vinyl-acetate copolymer encircled by a steroid hormone loaded ethylene-vinyl-acetate copolymer middle layer and a non-medicated outer layer of ethylene-vinyl-acetate copolymer. The device also contains a second compartment having a core of ethylene-vinyl-acetate copolymer loaded with a steroid hormone and a non-medicated outer layer of ethylene-vinyl-acetate copolymer.Type: GrantFiled: December 31, 1997Date of Patent: April 8, 2003Assignee: Akzo Nobel, N.V.Inventors: Rudolf Johannes Joseph Groenewegen, Antonius Paulus Sam, Herman Vromans, Hendrik de Nijs
-
Patent number: 6537566Abstract: The proliferation of uterine fibroid leiomyoma cells is inhibited by certain Fibroid Cell Growth Inhibitor (FGI) agents. The pharmacological doses of these FGI agents in the milieu of uterine fibroid cells can be made high enough to not only inhibit proliferation, but to also causes cell death. Non-invasive or minimally invasive, non-systemic delivery methods are used to deliver the FGI agent to the milieu of the target fibroid leiomyoma cell population, thereby avoiding the disadvantages and side effects of surgical and systemic hormonal therapy interventions in the treatment of uterine fibroids. The FGI agents are substrates that are normally present or are well tolerated in the human body. The efficacy of the FGI agents appears to be related to their ability to moderate the Protein Kinase C and Mitogen Activated Protein Kinase pathways. Specific FGI agents shown to be useful to inhibit growth or proliferation of uterine fibroid cells include: &agr;-tocopherol, &agr;-tocopherol succinate, and troglitazone.Type: GrantFiled: March 8, 2000Date of Patent: March 25, 2003Inventors: John Alton Copland, Steven L. Young
-
Patent number: 6455034Abstract: Methods, compositions and products are described which inhibit the development of odor in excreted body fluids by odor-causing cations.Type: GrantFiled: October 13, 1994Date of Patent: September 24, 2002Assignee: McNeil-PPC, Inc.Inventor: Fred H. Steiger
-
Publication number: 20020114824Abstract: In a method of producing an iron core by punching and laminating stator core pieces and rotor core pieces from the same metal sheet, it is an object of the invention that magnetic pole teeth of the roughly punched stator core pieces are caused to stably develop by pressing toward space sides made by previously punching the rotor core pieces so as to sufficiently secure punching margins for pressing out the front tips of the magnetic pole teeth of the internal forms of the stator core pieces and the punching can be performed without obstacles even if a gap with the rotor core pieces is small, and further ruggedness formed on a surface of the metal sheet by pressing does not cause disturbances in a flow of magnetic flux.Type: ApplicationFiled: January 16, 2002Publication date: August 22, 2002Inventors: Atsushi Fukui, Minao Isayama
-
Patent number: 6436428Abstract: Provided herein is a novel and useful device and method for locally delivering and controllably releasing oxybutynin in the cervical region of a female. A device of the invention comprises a ring comprising trifluoropropylmethyl/dimethyl siloxane elastomer. A pharmaceutical composition comprising oxybutynin and an excipient is placed within a bore located in the ring, wherein the bore runs from the surface of the ring into the ring. The ring has a sufficient size such that it can be inserted into the vaginal canal of a female. A cap comprising is placed over the bore at the surface of the ring in order to contain the pharmaceutical composition within the bore. When the ring is inserted into the vaginal canal, the trifluoropropylmethyl/dimethyl siloxane elastomer controllably releases and locally delivers a therapeutically effective amount of oxybutynin to the detrusor muscle to treat the female's urinary incontinence.Type: GrantFiled: March 21, 2000Date of Patent: August 20, 2002Assignee: Enhance Pharmaceuticals, Inc.Inventors: Anu Mahashabde, Martha Francine Kay, Donald F. Koelmel
-
Patent number: 6420336Abstract: The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention can be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the infectivity, replication and cytopathic effects of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.Type: GrantFiled: October 27, 1999Date of Patent: July 16, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Michael R. Boyd
-
Patent number: 6416779Abstract: Devices, methods, and compositions for treating vaginal fungal, bacterial, viral and parasitic infections by intravaginal or transvaginal administration of therapeutic and/or palliative antifungal, antibacterial, antiviral or parasiticidal drugs to the vagina or to the uterus.Type: GrantFiled: July 11, 2000Date of Patent: July 9, 2002Assignee: UMD, Inc.Inventors: Merida A. D'Augustine, James H. Liu, Donald C. Harrison
-
Patent number: 6416780Abstract: This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.Type: GrantFiled: May 1, 2000Date of Patent: July 9, 2002Assignee: Galen (Chemicals) LimitedInventors: Clare Passmore, Claire Gilligan
-
Patent number: 6361780Abstract: A drug delivery device is described comprising a porous biocompatible solid having at least one therapeutic drug within its pores, the therapeutic drug being removable from the pores by immersion in an aqueous solution. This may also be described as a drug delivery device comprising a porous annulus comprising a biocompatible solid having at least one therapeutic drug within its pores, the therapeutic drug being removable from the pores by immersion in an aqueous solution, the annulus having a top outer surface with an outside diameter, an inner surface with an inside diameter, and a side surface, at least one of the side surface and the top outer surface having openings of the pores exposed on that surface. The device may comprise pores having an average size of the greatest dimensions within the pores of between about 10−6 and 10−1 mm. The device may have a medical device or component of a medical device pass through an opening in the annulus.Type: GrantFiled: November 12, 1998Date of Patent: March 26, 2002Assignee: Cardiac Pacemakers, Inc.Inventors: Gregory R. Ley, Christopher Paul Knapp